Emily E. Renshaw

Emily counsels clients in regulatory matters concerning insider trading, accounting and disclosure issues, internal controls, whistleblower-related issues, and more. Individual directors, officers, and executives look to Emily to defend them in regulatory actions and private litigation where their reputations are at stake.

Active in pro bono work, Emily represents individuals and nonprofit organizations in investigations and litigation matters.

While in law school, Emily served as a judicial extern for Judge Nancy Gertner of the US District Court for the District of Massachusetts.

• Represented financial services firms in connection with SEC and CFTC investigations concerning the use of off-channel communications, as well as recordkeeping and books-and-records obligations
• Obtained dismissal of all claims in a putative securities class action against a biopharmaceutical company and certain of its officers and directors alleging false statements and omissions concerning the company’s CMC practices and New Drug Application (NDA) for a leading therapy
• Represented dozens of senior executives of a financial services firm in connection with an SEC investigation concerning the use of off-channel communications, as well as recordkeeping and books-and-records obligations
• Represented the audit committee of a publicly held food company in connection with an internal investigation of a whistleblower complaint concerning accounting issues
• Represented the CEO of a publicly held company in connection with an SEC investigation concerning accounting, disclosure, and internal control–related issues (investigation ongoing)
• Represented the audit committee of a publicly held food company in connection with an internal investigation concerning accounting, disclosure, and internal control–related issues
• Obtained dismissal with prejudice of all claims asserted in shareholder derivative action litigation against certain of Synchronoss Technologies’ senior officers and directors, where the plaintiffs alleged, among other things, that the company’s board breached its fiduciary duties in connection with the company’s sale of a business line
• Obtained dismissal with prejudice of all 1933 Act strict liability claims asserted against Casa Systems and certain of its directors and officers in a federal securities class action filed in New York and Massachusetts state courts, pursuant to the US Supreme Court’s ruling in the Cyan case, arising out of the initial public offering of Casa’s stock
• Represented a publicly held biopharmaceutical company and its current and former officers in an SEC investigation concerning the company’s public statements regarding the commercial viability of, and anticipated patient population for, a principal drug candidate (the SEC declined to bring an enforcement action)
• Represented Tempur Sealy in a federal securities fraud class action asserted against Tempur Sealy and its CEO and CFO following a stock drop triggered by the loss of the company’s largest customer, Mattress Firm; the court dismissed all claims
• Represented a publicly held global services company in an SEC investigation concerning the company’s accounting practices and internal controls following a whistleblower complaint (no action taken by the SEC)
• Second-chaired a Daubert hearing that resulted in the court denying class certification in a multibillion-dollar federal securities fraud class action against Freddie Mac, and the exclusion of plaintiff’s class certification expert’s testimony